Page 508 - Read Online

Page 8 of 9 Wu et al. J Cancer Metastasis Treat 2020;6:40 I http://dx.doi.org/10.20517/2394-4722.2020.77

Copyright
© The Author(s) 2020.

REFERENCES
1. Schiavo AL, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors:
facts and controversies. Clin Dermatol 2013;31:391-9.
2. Amber KT, Panganiban CM, Korta D, Feraudy S, Kelly KM, Grando SA. A case report of bullous pemphigoid associated with a
melanoma and review of the literature. Melanoma Res 2017;27:65-7.
3. Yatim A, Bohelay G, Grootenboer-Mignot S, et al. Paraneoplastic pemphigus revealed by anti-programmed Death-1 pembrolizumab
therapy for cutaneous squamous cell carcinoma complicating hidradenitis suppurativa. Front Med (Lausanne) 2019;6:249.
4. Kridin K, Bergman R. Assessment of the prevalence of mucosal involvement in bullous pemphigoid. JAMA Dermatol 2019;155:166-71.
5. Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of
histopathologic features. J Am Acad Dermatol 2020;83:1130-43.
6. Buonavoglia A, Leone P, Dammacco R, et al. Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy.
Autoimmun Rev 2019;18:349-58.
7. Nahmias Z P, Merrill ED, Briscoe CC, et al. Development of bullous pemphigoid while receiving PD-1 checkpoint inhibitor nivolumab.
SKIN J Cutane Med 2018:2:175-80.
8. Cuenca-Barrales C, Espadafor-López B, Martínez-López A, Cancela-Díez B, Ruiz-Villaverde R. Bullous pemphigoid in a patient treated
with nivolumab. Dermatol Ther 2019;32:e13030.
9. Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody
therapy: a report on bullous skin eruptions. J Cutan Pathol 2016;43:688-96.
10. Amber KT, Valdebran M, Kridin K, Grando SA. The role of eosinophils in bullous pemphigoid: a developing model of eosinophil
pathogenicity in mucocutaneous disease. Front Med (Lausanne) 2018;5:201.
11. Tampoia M, Giavarina D, Di Giorgio C, Bizzaro N. Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-
skin autoantibodies in autoimmune blistering skin diseases: a systematic review and meta-analysis. Autoimmun Rev 2012;12:121-6.
12. Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis
evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018;79:1081-8.
13. Sadik CD, Langan EA, Grätz V, Zillikens D, Terheyden P. Checkpoint inhibition may trigger the rare variant of anti-LAD-1 IgG-positive,
anti-BP180 NC16A IgG-negative bullous pemphigoid. Front Immunol 2019;10:1934.
14. Thomsen K, Diernaes J, Øllegaard TH, Spaun E, Vestergaard C. Bullous pemphigoid as an adverse reaction to pembrolizumab: two case
reports. Case Rep Dermatol 2018;10:154-7.
15. Kosche C, Owen JL, Sadowsky LM, Choi JN. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the
literature. Dermatol Online J 2019;25:6.
16. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid.
Arch Dermatol 1994;130:753-8.
17. Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA
Dermatol 2017;153:603-5.
18. Palla AR, Smith E, Doll D. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell
carcinoma. Immunotherapy 2019;11:1187-92.
19. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma:
characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22:886-94.
20. Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA
Dermatol 2015;151:1206-12.
21. Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid
tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 2019;7:341.
22. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does
checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 2019;39:147-64.
23. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-
L1. Cancer Immunol Res 2016;4:383-9.
24. Krenacs T, Kiszner G, Stelkovics E, et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can
mediate antibody induced melanoma apoptosis. Histochem Cell Biol 2012:138:653-7.
25. Papay J, Krenacs T, Moldvay J, et al. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray
approach. Appl Immunohistochem Mol Morphol 2007:15:19-30.
26. Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: Review of dermatologic toxicity associated with programmed cell
death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist 2018:23:1119-26.
27. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P. A case of bullous pemphigoid in a patient with metastatic melanoma
treated with pembrolizumab. Melanoma Res 2015;25:265-8.
28. Beck KM, Dong J, Geskin LJ, et al. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune